On Tuesday, Novavax (NVAX.O) announced that the World Health Organization (WHO) has authorized the emergency use of its updated COVID-19 vaccine for individuals aged 12 and older.<\/p>\n
This updated vaccine, which received approval in the U.S. last month, specifically targets a variant stemming from the XBB lineage of the coronavirus, which was globally prevalent earlier this year.<\/p>\n
The emergency use listing from the WHO is instrumental in expediting regulatory approvals for the import and administration of these vaccines by member states.<\/p>\n
Novavax faced challenges during the peak of the pandemic, causing delays in regulatory approval filing and missing out on the widespread success experienced by mRNA vaccine rivals.<\/p>\n
While Novavax’s original COVID shot received U.S. authorization in July 2022, its approval came later than those of Pfizer (PFE.N) and Moderna (MRNA.O).<\/p>\n
It’s noteworthy that Novavax’s updated shot employs a more conventional protein-based technology compared to the mRNA-based vaccines from Pfizer and Moderna.<\/p>\n
In response to this development, shares of Novavax, based in Maryland, showed a 1.8% increase to $5.6 in premarket trading.<\/p>\n","protected":false},"excerpt":{"rendered":"
On Tuesday, Novavax (NVAX.O) announced that the World Health Organization (WHO) has authorized the emergency use of its updated COVID-19 vaccine for individuals aged 12 and older. This updated vaccine,…<\/p>\n","protected":false},"author":1,"featured_media":4636,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[78],"tags":[],"class_list":["post-4633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulatory"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/regtechafrica.com\/healthcare\/wp-content\/uploads\/2023\/11\/WHO-authorizes-emergency-use-of-Novavaxs-updated-COVID-shot.jpg?fit=1200%2C675&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/4633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/comments?post=4633"}],"version-history":[{"count":1,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/4633\/revisions"}],"predecessor-version":[{"id":4637,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/4633\/revisions\/4637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media\/4636"}],"wp:attachment":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media?parent=4633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/categories?post=4633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/tags?post=4633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}